# Britannia Industries Ltd.

# Q1FY22 Result Update | FMCG

On ground situation improves, Innovative products restart



Equity Research Desk

August 3, 2021

Nifty Index

Rating	TP (Rs)	Up/Dn (%)
ACCUMULATE	3735	7
Market data		
Current price	Rs	3504
Market Cap (Rs.Bn)	(Rs Bn)	844
Market Cap (US\$ Mn)	(US\$ Mn)	11335
Face Value	Rs	1
52 Weeks High/Low	Rs 4	4004/3318
Average Daily Volume	('000')	23
BSE Code		500825
Bloomberg		BRIT:IN

# Source: Bloomberg

## **One Year Performance** 150 130 110 90 Aug-20 Nov-20 Jan-21 Apr-21 Jul-21

Britannia Industries Ltd

Source: Bloomberg

% Shareholding	Jun-21	Mar-21
Promoters	50.55	50.55
Public	49.45	49.45
Others	0.00	0.00
Total	100	100
Source: RSF		

# Britannia Consolidated O1FY22 better than expectations QoQ Revenues +8.7% and EBIDTA margins +20bps despite higher RM Revenue were flat -0.5% YoY to Rs 34035mn (+8.7% QoQ). Volume growth stood at 1% EBIDTA declined 22.8% YoY to Rs 5538mn (+9.6% QoQ) || EBIDTA margins 16.3% v/s 21% YoY and 16.1% QoQ **PAT (adj) declined** 28.6% YoY to Rs 3896mn (+7% QoQ) || tax rate 27.2% v/s 26.4% YoY (26.9% QoQ)

### **Other Details**

- Raw Materials to Revenue stood 61.3% v/s 58.3% (59.5% QoQ).
- Employee cost rose 1.7% YoY to Rs 1393.2mn (+12% QoQ)
- Other Expenses to Revenue stood at 18.3% v/s 16.7% (20.4% QoQ)
- **PBT** declined by 28% YoY to Rs 5309.7mn (+7.9% QoQ)

#### **Outlook:**

Cautious price increase to cover-up the inflation is expected to continue, EBIDTA margins in FY21 were exceptional @ 19.1%, aim would be to remain above the normalized historic margins of 15.9% i.e. FY20.

Q3FY21 had tapered off due to Rural however this year is expected to be better as things are better managed. Innovative and adjacent (on-the-go) products is expected to pick-up speed as pandemic issues reduces.

On the balance sheet side ICD exposure towards group companies -41% @ Rs 4.7bn

Financial Comme

Financiai S	ummary				
Y/E Mar (Rs	FY 19	FY 20	FY 21	FY 22E	FY 23E
Net sales	1,10,547	1,15,996	1,31,361	1,36,568	1,48,255
EBIDTA	17,334	18,432	25,092	22,737	25,982
Margins	15.7	15.9	19.1	16.6	17.5
PAT (adj)	11,591	14,155	18,643	16,910	19,997
growth (%)	15.4	22.1	31.7	(9.3)	18.3
EPS	48.2	58.9	77.4	70.2	83.0
P/E (x)	72.6	59.5	45.3	49.9	42.2
P/B (x)	19.8	19.1	23.8	19.2	15.6
EV/EBITDA (x	47.8	45.0	33.4	36.7	31.8
RoE (%)	27.3	32.1	52.6	38.5	37.1
ROCE (%)	35.5	27.9	40.8	32.0	33.4

Source: Dalal and Broacha

**Kunal Bhatia** +91 22 67141442 kunal.bhatia@dalal-broacha.com

# Conference Call KTA's continue

## Q1FY22 highlights

- July-21 was reasonably stable
- Volume growth Q1FY22 @ 1% || Q1FY21 Britannia was producing only 3 brands || Q1FY22 product mix was higher
- Market share gained in Q1FY22 as well
- Adjacent business i.e. out of home suffered and "home consumption" did well
- International business suffered due to container shortage
- Inflation YoY basis: Milk +13% || RPO +49% || flour -5% || Sugar -2% (on an overall level was 6-7%, including fuel price would be 1-2% higher)
- Ad Spends increased, brands returned on Air

## Network & Distribution highlights

- Direct Reach: 20.8 lac outlets v/s 23.7lac in March-21 (network getting back at base levels) || 90% of front-end is back now || 92% employees vaccinated with 1st dose
- Rural distribution @ 23k distributors flat v/s March-21 || coming back as situation improves
- Focus state growth was 1.33x of country average
- E-commerce sales contribution increased from 0.4% of sales to 2% (aim is to take it to 5%)
- Growth in channels is back @ 1.12x of FY20 (was 0.96x in FY21)|| modern trade, e-commerce and other channels expected to improve further
- Tech & Process improvement: S4 HANA, Arteria (for dealer management) & Ariba (procurement system) implemented || aided reducing inventory @ distributor level by 25%

#### Launches:

- Relaunched Goodday Chocochips (reponse is good)
- 50:50 Potazos Two in one format of Potato Chip and Biscuit ||started with N. East will launch in other states as well
- Milk Bikis atta launched pan India with new commercials || advertisement spends remains at high levels supported by above average growth in this product
- Innovations: had taken a back-seat on a/c of limited trial available

# Pipeline launches:

Milk Bikki classics (premium product) + health & wellness product in Nutrichoice

#### International business:

- Middle East distribution revamped
- Nepal Sales growth +26% || gained market share || aim to become larger
- Adding Egypt and Uganda to international portfolio.

3 August 2021 | 2 |

- Adjacent categories (including Milk @ 5% of Sales)
  contribute ~25bn to full year turnover
- Operational highlights
  - Flat wafers and Rolls plant in Tamil Nadu commercialized
  - Milk collection now 2x YoY at 50K a day
  - Ranjangaon 8 lines operational (110% incentives from state govt) || plant is now 10% of overall company's production || Dairy would be ready by Q3FY22 || YTD investment @ Rs 6.5bn (current turnover @ Rs1bn) @ full utilization will generate Rs 15bn revenue
  - CAPEX: planned @ Rs 1.3bn for FY22 (Gurgoan+Tamil Nadu+UP+Ranjangaon included)

3 August 2021 | 3 |

# **Quarterly Financials**

Particulars (Rs					
Mns) Consolidated	Q1FY22	Q1FY21	Growth	Q4FY21	Growth
Net Sales	33,519.4	33,844.6	-1.0%	30,381.3	10.3%
Other Op Income	515.2	362.1	42.3%	926.2	-44.4%
Total OP Income	34,034.6	34,206.7	-0.5%	•	8.7%
Add: O. Income	604.7	936.8	-35.5%	631.9	-4.3%
Total Income	34,639.3	35,143.5	-1.4%	31,939.4	8.5%
RAW MATERIALS	(20,865.1)	(19,959.0)	4.5%	(18,636.2)	12.0%
Employee Cost	(1,393.2)		1.7%	(1,242.0)	12.2%
O. Exps	(6,238.5)	(5,708.9)	9.3%	(6,375.4)	-2.1%
EBIDTA	6,142.5	8,106.1	-24.2%	5,685.8	8.0%
EBIDTA Less O. Inc	5,537.8	7,169.3	-22.8%	5,053.9	9.6%
Less Int	(342.1)				
Less Depn	(490.7)		2.3%	(528.2)	-7.1%
Less Exceptional	-	(0.9)		-	
PBT Before Exception	5,309.7	7,370.4	-28.0%	4,920.7	7.9%
PBT	5,309.7	7,369.5	-28.0%	4,920.7	7.9%
Less Tax	(1,441.7)	(1,943.7)	-25.8%	(1,325.8)	8.7%
Share of Profit/Loss					
from Associate	2.1	1.0	110.0%	5.8	-63.8%
Minority Interest	-	-		-	
PAT Reportd	3,870.1	5,426.8	-28.7%	3,600.7	7.5%
PAT Adjust ed					
Owner Share	3,895.5	5,457.9	-28.6%	3,643.2	6.9%
Equity	240.7	240.6		240.7	
EPS (Adjusted PAT)	16.2	22.7		15.1	
OPM	16.3%			16.1%	
NPM	11.2%			11.3%	
Tax Rate	-27.2%	-26.4%		-26.9%	
% to Operating Inco					
RAW MATERIALS	-61.3%			-59.5%	
Employee Cost	-4.1%			-4.0%	
O. Exps	-18.3%			-20.4%	
Total	-83.7%	-79.0%		-83.9%	

Source: Dalal & Broacha Research, Company

3 August 2021 | 4 |

# **Valuation**

Britannia is expected to report better sales going forward, also in Q3 and Q4 (last year) rural hinter-land which was impacted on account of pandemic is expected to bounce back.

With on-ground sales force getting back pace post vaccination and product mix improving trend going forward whould be positive.

At CMP of Rs 3503 Britannia trades at 50x FY22e EPS of Rs 70.2 and 42.5x FY23e EPS of Rs 83. We maintain Accumulate with a price target of Rs 3735.

3 August 2021 | 5 |

# **Financials**

P&L (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E	Cash Flow St. (Rs. mn)	FY19	FY20	FY21E	FY22E	
et Operating Income	1,10,546.7	1,15,995.5	1,31,361.4	1,36,568.0	1,48,255.5	Net Profit	11,591.2	14,026.3	18,639.0	16,909.7	1
						Add: Dep. & Amort.	1,618.8	1,848.1	1,978.5	2,175.5	
Raw materials	(65,614.6)	(69,274.7)	(76,261.0)	(81,564.9)	(87,026.0)	Cash profits	13,210.0	15,874.4	20,617.5	19,085.1	22
Employee costs	(4,418.2)	(4,866.9)	(5,273.8)	(5,695.7)	(6,208.3)	p	,	,	,	,	
Other Expenses	(23,179.7)	(23,422.1)	(24,734.3)	(26,570.6)	(29,039.2)	(Inc)/Dec in					
Cost of sales	(93,212.5)			(1,13,831.2)		-Sundry debtors	(896.4)	738.8	630.9	(102.0)	
cost of suics	(55,212.5)	(57,505.7)	(1,00,203.1)	(1,13,031.2)	(1,22,273.3)	-Inventories	(1,285.9)	404.2	(3,505.3)	1,186.8	
Operating Profit	17,334.2	18,431.8	25,092.3	22,736.8	25,982.0	-Loans/advances	(2,829.7)	(1,507.3)	786.8	(509.4)	
Depreciation	(1,618.8)	(1,848.1)	(1,978.5)	(2,175.5)	(2,411.8)	-Sundry creditors	1,464.2	(242.3)	1,984.7	(633.4)	
PBIT	15,715.4	16,583.7	23,113.8	20,561.3	23,570.2	-Others	772.5	872.4	2,534.4	313.4	
	,							265.8			
Other income	2,064.5	2,794.0	3,129.3	3,191.0	3,789.9	Change in working capital	(2,775.3)		2,431.5	255.3	21
Interest	(90.9)	(769.0)	(1,109.0)	(1,362.4)	(865.7)	CF from Oper. activities	10,434.7	16,140.2	23,049.0	19,340.4	21
Profit before tax	17,689.0	18,608.7	25,134.1	22,389.9	26,494.3	ont i did	(0.000.0)	/\	(==a =\	(= 000 a)	
Extraordinary Items / Exce		(170.1)				CF from Inv. activities	(8,000.0)	(17,299.5)	(770.5)	(5,000.0)	(5
Profit before tax (post Exc		18,438.6	25,134.1	22,389.9	26,494.3						
Provision for tax	(6,124.7)	(4,507.0)	(6,630.2)	(5,635.5)	(6,668.6)	CF from Fin. activities	(3,200.7)	1,289.6	(21,393.6)	(9,308.4)	(13
Reported PAT	11,564.3	13,931.6	18,503.9	16,754.3	19,825.7						
Share of Pft and Loss of											
Associates and Minority											
nt	26.9	94.7	141.2	155.3	170.9	Cash generated/(utilise	(766.0)	130.3	884.9	5,032.0	2
Adjust ed PAT	11,591.2	14,154.8	18,643.5	16,909.7	19,996.6	Cash at start of the year	1,864.2	1,098.2	1,228.5	2,113.4	7
						Cash at end of the year	1,098.2	1,228.5	2,113.4	7,145.4	(
Balance Sheet	FY19	FY20	FY21E	FY22E	FY23E	Ratios	FY19	FY20	FY21E	FY22E	
Equity capital	240.3	240.5	240.9	240.9	240.9	OPM	15.7	15.9	19.1	16.6	
Reserves	42,292.2	43,787.8	35,235.7	43,690.5	53,688.8	NPM	10.3	11.9	13.9	12.1	
Net worth	42,532.5	44,028.3	35,476.6	43,931.4	53,929.7	Tax rate	(34.6)	(24.4)	(26.4)	(25.2)	
nee worth	12,332.3	11,020.3	33, 17 0.0	13,331.1	33,323.7	Tux Tucc	(5 1.0)	(2 1.1)	(20.1)	(23.2)	
Def. Tax Liab.+Minority Int	326.8	356.5	363.4	509.8	670.9	Growth Ratios (%)					
Secured loans	619.2	7,660.6	7,477.5	6,477.5	4,477.5	Net Sales	11.5	4.9	13.2	4.0	
Unsecured loans	761.0	7,479.9	13,394.2	13,394.2	11,394.2	Operating Profit	15.4	6.3	36.1	(9.4)	
Total debt	1,380.2	15,140.5	20,871.7	19,871.7	15,871.7	PAT	15.4	22.1	31.7	(9.3)	
CAPITAL EMPLOYED	44,239.5	59,525.3	56,711.7	64,312.9	70,472.3						
						Per Share (Rs.)					
Gross block	20,294.0	23,954.9	25,111.8	27,611.8	30,611.8	Net Earnings (EPS)	48	59	77.4	70.2	
Accumulated depreciation		(6,562.8)	(8,541.3)	(10,716.8)	(13,128.6)	Cash Earnings (CPS)	55	66	86	79	
Net block	15,579.3	17,392.1	16,570.5	16,895.0	17,483.2	Dividend	15.0	35.0	145.0	35.1	
	1,012.4	395.5				Book Value	177.0	183.1	147.3	182.4	
Total fixed assets	16,591.7	17,787.6	17,735.7	18,060.2	18,648.4	Free Cash Flow	10.13	(4.82)	92.48	59.53	
Goodwill	1,303.7	1,389.7	1,359.0	1,359.0	1,359.0		. 0 3	(1.02)	22.10	33.33	
Investments	14,762.8	28,932.3	27,806.9	30,306.9	32,806.9	Valuation Ratios					
Inventories	7,813.8	7,409.6	10,914.9	9,728.1	10,560.7	P/E(x)	72.6	59.5	45.3	49.9	
Sundry debtors	3,942.4	3,203.6	2,572.7	2,674.7	2,903.6	P/B(x)	19.8	19.1	23.8	19.2	
Cash & bank											
	1,098.2	1,228.5	2,113.4	7,145.4	9,538.5	EV/EBIDTA(x)	47.8	45.0	33.4	36.7	
Loans & advances	12,229.4	13,130.6	10,211.4	10,211.4	10,211.4	Div. Yield(%)	0.4	1.0	4.1	1.0	
Other current assets	4,538.7	5,144.8	7,277.2	7,786.6	8,331.7	FCF Yield(%)	0.3	(0.1)	2.6	1.7	
Sundry creditors	(11,405.1)		(13,147.5)	(12,514.1)	(13,113.5)						
O. Current Liablities	(4,655.3)	(5,563.1)	(6,267.0)	(6,580.4)	(6,909.4)	Return Ratios (%)					
Provisions	(2,079.6)	(2,044.2)	(3,874.7)	(3,874.7)	(3,874.7)	ROE	27.3	32.1	52.6	38.5	
Working capital	11,482.5	11,347.0	9,800.4	14,577.1	17,648.3	ROCE	35.5	27.9	40.8	32.0	
Deferred Tax Assets	98.8	68.7	9.7	9.7	9.7						
Miscellaneous exp.	-	-	-	-	-						
	44,239.5	59,525.3	56,711.7	64,312.9	70,472.3						

Source: Dalal & Broacha Research, Company

3 August 2021 | 6 |

#### Disclaimer

**Dalal & Broacha Stock Broking Pvt Ltd, hereinafter referred to as D&B** (CINU67120MH1997PTC111186) was established in 1997 and is an integrated financial services player offering an extensive range of financial solutions and services to a wide spectrum of customers with varied needs ranging from equities to mutual funds to depository services. D&B is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). D&B along with its affiliates offers the most comprehensive avenues for investments and is engaged in the securities businesses including stock broking (Institutional and retail), depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.dalal-broacha.com

D&B is registered as Research Analyst with SEBI bearing registration Number INH000001246 as per SEBI (Research Analysts) Regulations, 2014.

D&B hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in any time in the past. It has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time. SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on D&B for certain operational deviations in routine course of business.

D&B offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by D&B (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

D&B or its associates may have financial interest in the subject company.

D&B or its associates do not have any material conflict of interest in the subject company.

The Research Analyst or Research Entity (D&B) has not been engaged in market making activity for the subject company.

D&B or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

#### Disclosures in respect of Research Analyst:

Whether Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of	No
publication of Research Report:	
Whether the Research Analyst or his/her relative's financial interest in the subject company.	No
Whether the research Analyst has served as officer, director or employee of the subject company	No
Whether the Research Analyst has received any compensation from the subject company in the	No
past twelve months	
Whether the Research Analyst has managed or co-managed public offering of securities for the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report	No

D&B and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

3 August 2021 | 7 |

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject D&B or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to D&B. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of D&B. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of D&B or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Name	Designat ion	Email	Phone	Sector
Mr. Kunal Bhatia	Head of Research	kunal.bhatia@dalal-broacha.com	022 67141442	Auto   Auto Ancillary   FMCG
Mrs.Charulata Gaidhani	Sr. Analyst	<u>charulata.gaidhani@dalal-broacha.com</u>	022 67141446	Pharma   Healthcare
Mr. Mayank Babla	Sr. Analyst	mayank.babla@dalal-broacha.com_	022 67141412	IT   Telecom   Media
Mr. Avinash Tanawade	Sr. Analyst	avinash.tanawade@dalal-broacha.com_	022 67141449	BFSI
Mr. Akshay Ashok	Analyst	akshay.ashok@dalal-broacha.com_	022 67141486	BFSI
Ms. Timshar Dhamodiwala	Associate	timshar.dhamodiwala@dalal-broacha.com_	022 67141441	IT   Telecom   Media

Address: - 508, Maker Chambers V, 221 Nariman Point, Mumbai 400 021.

Tel: 91-22- 2282 2992, 2287 6173, Fax: 91-22-2287 0092 E-mail: equity.research@dalal-broacha.com

3 August 2021 | 8 |